The Receptor-associated Protein (RAP) As A Molecular Chaperone For The Amyloid Protein (Abeta) Of Alzheimers Disease
Funder
National Health and Medical Research Council
Funding Amount
$402,403.00
Summary
Our research will examine the role of a protein known as the receptor-associated protein (RAP) in Alzheimer's disease. We will determine whether the protein contributes to the progression of Alzheimer's disease and we will examine the possiblity that that RAP may be used as a drug to treat the disease. The project could potentially have direct benefit for patients by leading to an effective treatment for dementia associated with Alzheimer's disease.
Cholinergic Abnormalities In Alzheimer's Disease: Identification Of Novel Therapeutic Targets
Funder
National Health and Medical Research Council
Funding Amount
$478,500.00
Summary
The aim of this project is to develop new drugs for the treatment of Alzheimer's disease. Alzheimer's disease is a disease of ageing commonly associated with memory loss. The disease is caused by the build up of amyloid protein in the brain. However, it is not known how amyloid protein causes degeneration of normal brain function. Our previous studies have shown that amyloid protein targets two components which are important for normal brain function. These components are 1) acetylcholinesterase ....The aim of this project is to develop new drugs for the treatment of Alzheimer's disease. Alzheimer's disease is a disease of ageing commonly associated with memory loss. The disease is caused by the build up of amyloid protein in the brain. However, it is not known how amyloid protein causes degeneration of normal brain function. Our previous studies have shown that amyloid protein targets two components which are important for normal brain function. These components are 1) acetylcholinesterase and 2) nicotinic receptors, which are known to be important for memory. The aim of this application is to identify the mechanisms by which amyloid protein targets acetylcholinesterase and nicotinic receptors and to design inhibitors of this interaction which may ultimately provide a platform for future drug development.Read moreRead less